ATTO-1091
/ Attovia Therap
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 16, 2026
Safety, Tolerability and PK of ATTO 1091 in Healthy Adult Volunteers and Patients With Ulcerative Colitis
(clinicaltrials.gov)
- P1 | N=96 | Not yet recruiting | Sponsor: Attovia Therapeutics Inc
New P1 trial • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis
1 to 1
Of
1
Go to page
1